Clinical trials play a vital role in generating revenue for Israeli hospitals and providing patients with access to cutting-edge medical advancements from around the world. However, in 2023, there was a noticeable decrease in the volume of clinical trials conducted in local hospitals, resulting in a decrease in hospital revenues to NIS 518 million from NIS 818 million in 2022. This marked the lowest figure since 2014, with a 15% decrease compared to the previous record year of 2021.
There were several factors that contributed to this reduction in research volume, including the impact of the war and political crisis as well as the global decline in clinical trials following the peak of 2021-2022 driven by the COVID-19 pandemic. Despite these challenges, some hospitals like Sheba Hospital in Tel Hashomer and Rambam Hospital in Haifa continue to lead in conducting clinical trials in Israel.
Major pharmaceutical companies such as Merck & Co., AbbVie, AstraZeneca, Janssen Pharmaceuticals, Eli Lilly, Genentech (Roche), Novartis, Pfizer, and Amgen are among the top customers for clinical trials conducted at Israeli hospitals. Their investment showcases a commitment to advancing medical science and improving patient care.
